Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04640935
Other study ID # 19-09
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 1, 2019
Est. completion date June 5, 2020

Study information

Verified date November 2020
Source Centre Hospitalier Annecy Genevois
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of the study is to evaluate the paclitaxel-bevacizumab combination retrospectively and multicenter in current practice, with subgroup analyses of the following patients: patients who have previously received immunotherapy, patients with an EGFR or ALK oncogenic addiction pathway, patients who have previously received taxanes or anti-angiogenic agents.


Description:

Lung and bronchopulmonary cancer is the leading cause of cancer death in France and worldwide. It is diagnosed at the metastatic stage from the outset in approximately 50% of cases. Non-small cell lung cancers (NSCLC) are the most frequent histological forms of lung cancer (approximately 85% of cases) with a predominance of the non-epidermal type. The increase in the number of treatments available, improved supportive care and better patient selection have, in recent years, made it possible to expand the range of first-line chemotherapy treatments available at delà̀ and have contributed to the increase in overall survival (OS). As a result, nearly 80% of patients with metastatic NSCLC receive a second line of treatment. The main objective in these often symptomatic patients is a satisfactory tumor control rate with acceptable tolerability. For a long time, the second-line reference chemotherapy has been docetaxel or pemetrexed as monotherapy with modest results. Alternative treatments such as the combination of paclitaxel (chemotherapy)-bevacizumab (anti-angiogenic monoclonal antibody) have been studied. Since 2010, by analogy with breast cancer and in the absence of therapeutic alternatives, the paclitaxel-bevacizumab doublet has been used in non-epidermal stage IV NSCLC in France. The value of combining taxane chemotherapy with an anti-angiogenic molecule has been demonstrated in two Phase 3 clinical trials. Thus, this combination is an integral part of the possible treatments in 2nd line and beyond, registered since 2016 in the treatment guidelines for non-epidermal NSCLC. The first-line therapeutic strategy will also be redefined in 2019 with the use of immunotherapy for a majority of patients. Subsequent treatment lines will be modified, with a focus on chemotherapy, in particular the paclitaxel-bevacizumab combination. As this combination has been used in current practice for several years, and in view of the upcoming changes to the first and second line of NSCLC treatment, data on the efficacy and tolerance of this combination in real life are needed to guide our practices. Recent studies are also looking at the efficacy of chemotherapy, particularly taxane chemotherapy associated with an anti-angiogenic agent after a previous line including immunotherapy, with a favorable signal. The aim of the study is to evaluate the paclitaxel-bevacizumab combination retrospectively and multicenter in current practice, with subgroup analyses of the following patients: patients who have previously received immunotherapy, patients with an EGFR or ALK oncogenic addiction pathway, patients who have previously received taxanes or anti-angiogenic agents.


Recruitment information / eligibility

Status Completed
Enrollment 320
Est. completion date June 5, 2020
Est. primary completion date June 5, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - At least 18 years old; - Histologically or cytologically confirmed diagnosis of non-epidermal NSCLC; - Advanced stage IV disease at the start of treatment with paclitaxel-bevacizumab according to TNM 7/8th edition classification; - Treatment with paclitaxel-bevacizumab received as second-line therapy or beyond, in a clinical trial or not; - Alive patients not opposed to the use of their data Exclusion Criteria: - Patient under guardianship or curatorship at the date of the study ; - Patients alive at the time of the study who are opposed to the use of their data - Opposition to the use of their data expressed during the lifetime of patients who died at the time of the study.

Study Design


Locations

Country Name City State
France Hôpital Ambroise Paré AP-HP Boulogne Billancourt
France Centre Hospitalier Universitaire Brest Brest
France Centre Hospitalier Métropole Savoie Chambéry
France Centre Hospitalier Intercommunal de Créteil Créteil
France Centre Hospitalier Universitaire Grenoble Alpes Grenoble
France Centre Hospitalier de Versailles André Mignot Le Chesnay
France Centre Hospitalier Universitaire de Lille Lille
France Centre Léon Bérard Lyon Lyon
France Hospices Civils de Lyon Lyon
France Centre Hospitalier François Quesnay Mantes-la-Jolie
France Centre Hospitalier Annecy Genevois Metz-Tessy
France Institut Curie Paris
France Institut Curie Saint Cloud Saint-Cloud
France Institut de Cancérologie Lucien Neuwirth Saint-Étienne
France Hôpital Foch Suresnes

Sponsors (2)

Lead Sponsor Collaborator
Centre Hospitalier Annecy Genevois University Hospital, Grenoble

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival Progression-free survival with paclitaxel-bevacizumab, i.e., the time from the start of paclitaxel-bevacizumab treatment to cancer progression, estimated at 12 months in the general population. Up to 12 months
Secondary Drugs administration dosage description Description of the different monthly drug administration regimens Up to 12 months
Secondary Objective response rate and control rate Objective response rate and control rate according to RECIST 1.1 criteria in the general population Up to 12 months
Secondary Overall survival Rate Overall survival, assessed on the whole population Up to 12 months
Secondary Objective Response Rate Objective Response Rate in the following subgroups:
patients treated after immunotherapy and especially immediately after immunotherapy;
Patients with an oncogenic EGFR or ALK addiction pathway;
Patients previously treated with taxanes;
Patients previously treated with anti-angiogenic drugs;
Up to 12 months
Secondary Progression-Free Survival Rate Progression-Free Survival in the following subgroups:
patients treated after immunotherapy and especially immediately after immunotherapy;
Patients with an oncogenic EGFR or ALK addiction pathway;
Patients previously treated with taxanes;
Patients previously treated with anti-angiogenic drugs;
Up to 12 months
Secondary Disease Control Rate Disease Control in the following subgroups:
patients treated after immunotherapy and especially immediately after immunotherapy;
Patients with an oncogenic EGFR or ALK addiction pathway;
Patients previously treated with taxanes;
Patients previously treated with anti-angiogenic drugs;
Up to 12 months
Secondary Overall Survival Rate Overall Survival in the following subgroups:
Patients treated after immunotherapy and especially immediately after immunotherapy;
Patients with an oncogenic EGFR or ALK addiction pathway;
Patients previously treated with taxanes;
Patients previously treated with anti-angiogenic drugs;
Up to 12 months
Secondary Frequency of safety events Frequency of grade =3 adverse events and frequency of discontinuation of paclitaxel-bevacizumab for toxicity ; Up to 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Completed NCT01945021 - Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC Phase 2
Completed NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Terminated NCT04022876 - A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) Phase 1
Recruiting NCT05898763 - TEIPP Immunotherapy in Patients With NSCLC Phase 1/Phase 2
Recruiting NCT05532696 - Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients Phase 1/Phase 2
Completed NCT04311034 - A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Terminated NCT03257722 - Pembrolizumab + Idelalisib for Lung Cancer Study Phase 1/Phase 2
Completed NCT00349089 - Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy Phase 2
Completed NCT05116891 - A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04571632 - Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors Phase 2
Terminated NCT03599518 - DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Phase 1
Not yet recruiting NCT06020989 - Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy Phase 2
Withdrawn NCT03982134 - PDR001 + Panobinostat for Melanoma and NSCLC Phase 1
Withdrawn NCT03574649 - QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer Phase 2
Withdrawn NCT02844140 - DE-CT in Lung Cancer Proton Therapy N/A
Completed NCT03780010 - Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC Phase 1